Midatech, a global leader in the design, synthesis and manufacture of nanomedicines based on its unique gold-nanoparticle (drug delivery technology, has appointed Dr Jim Philips as Chief Executive Officer.
Dr Philips has more than 25 years of senior management and board level experience in public and private companies across Europe, the US and Australia.
He joins Midatech from Healthcare Brands International, the UK consumer healthcare company, where he has been CEO since 2010. Between 2007 and 2012 he served as Non-executive Chairman of Prosonix, a speciality pharmaceutical company developing respiratory medicines using an innovative particle-engineering technology and approach.
Before joining HBI, Dr Phillips was CEO of Vantia, a pharmaceutical company developing novel, small molecule drugs. Prior to that he founded and served as CEO of Talisker Pharma until its acquisition by EUSA in 2006, when he became President of EUSA Pharma Europe. Dr Phillips has also held senior roles in drug and business development in Novartis and Johnson & Johnson.
